MX2020008030A - Anticuerpos de glipicano 3 y conjugados de los mismos. - Google Patents
Anticuerpos de glipicano 3 y conjugados de los mismos.Info
- Publication number
- MX2020008030A MX2020008030A MX2020008030A MX2020008030A MX2020008030A MX 2020008030 A MX2020008030 A MX 2020008030A MX 2020008030 A MX2020008030 A MX 2020008030A MX 2020008030 A MX2020008030 A MX 2020008030A MX 2020008030 A MX2020008030 A MX 2020008030A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- antibodies
- glypican
- gpc3
- chimeric
- Prior art date
Links
- 102000010956 Glypican Human genes 0.000 title 1
- 108050001154 Glypican Proteins 0.000 title 1
- 108050007237 Glypican-3 Proteins 0.000 title 1
- 102100032530 Glypican-3 Human genes 0.000 abstract 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona anticuerpos murinos, quiméricos y humanizados que se unes específicamente a GPC3 y sus conjugados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631353P | 2018-02-15 | 2018-02-15 | |
PCT/US2019/018182 WO2019161174A1 (en) | 2018-02-15 | 2019-02-15 | Glypican 3 antibodies and conjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008030A true MX2020008030A (es) | 2020-09-10 |
Family
ID=67620075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008030A MX2020008030A (es) | 2018-02-15 | 2019-02-15 | Anticuerpos de glipicano 3 y conjugados de los mismos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11819553B2 (es) |
EP (1) | EP3752534A4 (es) |
JP (2) | JP7402807B2 (es) |
KR (1) | KR20200121317A (es) |
CN (1) | CN111712520A (es) |
AR (1) | AR114112A1 (es) |
AU (1) | AU2019220700A1 (es) |
CA (1) | CA3090251A1 (es) |
IL (1) | IL276514A (es) |
MX (1) | MX2020008030A (es) |
SG (1) | SG11202007073SA (es) |
TW (1) | TW201938587A (es) |
WO (1) | WO2019161174A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA45945A (fr) | 2016-08-09 | 2019-06-19 | Seattle Genetics Inc | Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées |
AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
IL295774A (en) * | 2020-02-27 | 2022-10-01 | Nanjing Legend Biotech Co Ltd | Antibodies and chimeric antigen receptors directed against glypican-3 (gpc3) and methods of using them |
BR112022020332A2 (pt) | 2020-04-10 | 2022-12-13 | Seagen Inc | Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune |
BR112022020716A2 (pt) * | 2020-05-07 | 2022-11-29 | Phanes Therapeutics Inc | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos |
BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
CN112921005B (zh) * | 2021-04-14 | 2023-07-07 | 中国农业科学院兰州兽医研究所 | 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用 |
WO2022251850A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
WO2023045151A1 (en) * | 2021-09-24 | 2023-03-30 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against gpc3 and uses thereof |
TW202400137A (zh) | 2022-03-17 | 2024-01-01 | 美商思進公司 | 喜樹鹼偶聯物 |
WO2023207475A1 (zh) * | 2022-04-24 | 2023-11-02 | 昱言科技(北京)有限公司 | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 |
WO2024061305A1 (zh) * | 2022-09-22 | 2024-03-28 | 上海美雅珂生物技术有限责任公司 | Gpc3抗体药物偶联物及其应用 |
WO2024114410A1 (zh) * | 2022-11-28 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 靶向gpc3的抗体及其用途 |
WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
KR100877176B1 (ko) | 2001-06-22 | 2009-01-07 | 츄가이 세이야꾸 가부시키가이샤 | 항글리피칸 3항체를 포함하는 세포증식 억제제 |
AU2002338020A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
BRPI0506125B8 (pt) * | 2004-07-09 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo anti - glipicano 3, seu método de produção, polinucleotídeo, vetor e inibidor do crescimento de células |
MX343228B (es) | 2009-11-30 | 2016-10-26 | Biotest Ag | Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso. |
CN113933504A (zh) * | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
CA2946662A1 (en) * | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
EP2963057A1 (en) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
EP3900742B1 (en) * | 2014-09-11 | 2024-05-15 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
WO2017181109A1 (en) * | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
US20170326249A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
-
2019
- 2019-02-14 AR ARP190100366A patent/AR114112A1/es unknown
- 2019-02-15 SG SG11202007073SA patent/SG11202007073SA/en unknown
- 2019-02-15 CN CN201980012811.4A patent/CN111712520A/zh active Pending
- 2019-02-15 KR KR1020207025196A patent/KR20200121317A/ko unknown
- 2019-02-15 WO PCT/US2019/018182 patent/WO2019161174A1/en unknown
- 2019-02-15 US US16/970,095 patent/US11819553B2/en active Active
- 2019-02-15 EP EP19755133.6A patent/EP3752534A4/en active Pending
- 2019-02-15 CA CA3090251A patent/CA3090251A1/en active Pending
- 2019-02-15 AU AU2019220700A patent/AU2019220700A1/en active Pending
- 2019-02-15 JP JP2020543351A patent/JP7402807B2/ja active Active
- 2019-02-15 TW TW108105041A patent/TW201938587A/zh unknown
- 2019-02-15 MX MX2020008030A patent/MX2020008030A/es unknown
-
2020
- 2020-08-05 IL IL276514A patent/IL276514A/en unknown
-
2023
- 2023-04-17 JP JP2023067166A patent/JP2023089195A/ja active Pending
- 2023-10-13 US US18/486,335 patent/US20240173427A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021513844A (ja) | 2021-06-03 |
TW201938587A (zh) | 2019-10-01 |
JP7402807B2 (ja) | 2023-12-21 |
US11819553B2 (en) | 2023-11-21 |
IL276514A (en) | 2020-09-30 |
WO2019161174A1 (en) | 2019-08-22 |
CA3090251A1 (en) | 2019-08-22 |
US20240173427A1 (en) | 2024-05-30 |
EP3752534A4 (en) | 2021-12-01 |
SG11202007073SA (en) | 2020-08-28 |
EP3752534A1 (en) | 2020-12-23 |
AR114112A1 (es) | 2020-07-22 |
US20210361776A1 (en) | 2021-11-25 |
JP2023089195A (ja) | 2023-06-27 |
KR20200121317A (ko) | 2020-10-23 |
AU2019220700A1 (en) | 2020-09-24 |
CN111712520A (zh) | 2020-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008030A (es) | Anticuerpos de glipicano 3 y conjugados de los mismos. | |
NZ736728A (en) | Cd123 antibodies and conjugates thereof | |
MX2017011432A (es) | Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados. | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
IL277072A (en) | Anti-claudin antibodies 18.2 | |
PH12018501042A1 (en) | Antibodies and antibody fragments for site-specific conjugation | |
IL280467A (en) | Antibody constructs for CLDN18.2 and CD3 | |
MX2018008592A (es) | Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos. | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
PH12019500552A1 (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
PH12019500551A1 (en) | Antibody specifically binding to il-17a and functional fragment thereof | |
EP3411069A4 (en) | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | |
MX2021007274A (es) | Molecula bifuncional anti-pd-1/sirpa. | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
MX2021002710A (es) | Anticuerpos anti-c5 humanizados y usos de los mismos. | |
IL286696A (en) | Human anti-claudin 18.2 chimeric antigen receptors and uses thereof | |
MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. | |
EP3902838A4 (en) | CD30 BINDING FRACTIONS, CHEMERA ANTIGEN RECEPTORS AND THEIR USES | |
MX2021000797A (es) | Anticuerpos agonistas de cd226. | |
MX2014010987A (es) | Tratamiento de esclerosis multiple con anticuerpo anti-cd19. | |
MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
GB201818618D0 (en) | Monoclonal antibodies against ambra-1 | |
EP3656791A4 (en) | HUMAN ANTI-CCR1 MONOCLONAL ANTIBODY |